Sandbox Reserved 1110

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: {{Sandbox_ESBS_2019}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' caption='Cap...)
Current revision (15:05, 17 January 2020) (edit) (undo)
 
(35 intermediate revisions not shown.)
Line 1: Line 1:
{{Sandbox_ESBS_2019}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
{{Sandbox_ESBS_2019}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->
-
==Your Heading Here (maybe something like 'Structure')==
 
-
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
 
-
This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
 
-
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
 
-
== Function ==
 
-
== Disease ==
 
-
== Relevance ==
 
-
== Structural highlights ==
+
==5LSD==
 +
<StructureSection load='5LSD' size='350' side='right' caption='Mouse recombinant Nerve Growth Factor (PDB entry [[5LSD]])' scene=''>
-
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
+
==General informations==
 +
Total Structure Weight: '''26554.02 Da'''
 +
 +
Atom Count: '''1860'''
 +
 +
Residue Count: '''236'''
 +
 +
5LSD is the recombinant mouse '''Nerve Growth Factor (NGF)''', that does not bind to '''any ligand'''. Therefore it allows conclusions on the features of its binding loops, i.e. the NGF N-Terminus structure in absence of ligands. Further, the flexibility of the loops can be targeted through 5LSD as well as their impact on the overall structural plasticity of mature NGF. 5LSD also clarifies about the loops´ contribution to antibody recognition. <ref>PMID: 28083536</ref>
 +
 +
== Structure ==
 +
 +
Since the X-ray crystal structure of NGF has been known since the ‘90s, the general structure of 5LSD can be described by relatable structures such as a <scene name='82/829363/Feuillets_beta/1'>β-sandwich fold</scene>, with '''four loop regions''' (<scene name='82/829363/Loop_i2/1'>I</scene>,<scene name='82/829363/Loops_ii/1'>II</scene>,<scene name='82/829363/Loops_iii/1'>III</scene> and <scene name='82/829363/Loops_v/1'>V</scene>) which are the center of interactions with ligands but which are inactive in the case of 5LSD.
 +
 +
In this PDB representation, there are two 118 amino acids chains, <scene name='82/829363/Chain_a/3'>chain A</scene> and <scene name='82/829363/Chain_b/1'>chain B</scene>, which are similar to the residues NGF ones, except for <scene name='82/829363/No_ngf/1'>these fragments</scene>, proper to 5LSD. [https://www.ncbi.nlm.nih.gov/Structure/pdb/5LSD]
 +
 +
In the absence of partners, the NGF N-terminus has a strong tendency to fold into a <scene name='82/829363/Helix_n-terminus/1'>helix</scene>. This challenges the current view that this region is unstructured. Experiments have shown that this N-terminus plays an important role in many processes, and its absence triggers a loss of affinity with the receptor '''TrkA'''. The loops, especially II and V, and the C-terminus are relatively more flexible than the more rigid β-sheet regions (showing hetNOE values lower than the average of 0.7). However, the loop variations are relatively small compared to the flexibility of the N- and C-termini, which indicates that the loops are plastic but not flexible. <ref>PMID: 28083536</ref>
 +
 +
== The neurotrophin family ==
 +
 +
The neurotrophins gather the proteins involved in many mechanisms essential for the growth, maintenance and survival of neuronal populations, As NGF is the prototype of this family, each recombinant form of it targets a special population of neurons in the central as well as in the peripheral nervous system. Each member of this family plays a role on the activation of one of the three tropomyosin-related kinase ('''Trk''') [http://proteopedia.org/wiki/index.php/High_affinity_nerve_growth_factor_receptor] receptor ('''TrkA, TrkB, and TrkC''') and activates the '''p75''' neurotrophin receptor, a member of the tumor necrosis factor receptor superfamily.
 +
The members of the neurotrophin family are then as useful in prenatal organisms for the development of cortexes and in adulthood, where they control synaptic function and plasticity and sustain neuronal cell survival.
 +
 +
== Diseases and use in Biotechnologies/ Relevance ==
 +
 +
As NGF is the prototype of the neurotrophin family, a better understanding of NGF could lead to a better understanding of the whole family. A better knowledge of NGF, i.e. through 5LSD, is supportive.
 +
 +
It has been shown that Alzheimer’s Disease and the ratio of ProNGF/NGF ('''ProNGF''' being the pre-mutine form of NGF) are linked <ref>PMID: 23538417</ref> , and that this ratio plays a role in neurodegeneration. The matter would be to understand how the different forms of NGF interact, then being able to understand the interactions between the ligands and the loops by modifying the 5LSD structure could help in the medical way. Moreover, it has been experimentally and clinically shown that NGF plays a role in the '''pain states'''. Understanding and developing anti-NGF could advance the research of safe and efficient analgesics. <ref>PMID:24691709</ref>
 +
In fact, NGF fragments would also lead scientist to their anti-NGF as 5LSD permitted to detect the anti-NGF antagonist antibody '''αD11'''.
 +
 +
The NMR structure of 5LSD lead to the conclusion that NGF has long plastic but relatively rigid loops, which is of crucial importance for future drug design.<ref>PMID: 24691709</ref>
 +
</StructureSection>
</StructureSection>
 +
== References ==
== References ==
<references/>
<references/>

Current revision

This Sandbox is Reserved from 25/11/2019, through 30/9/2020 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1091 through Sandbox Reserved 1115.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing



5LSD

Mouse recombinant Nerve Growth Factor (PDB entry 5LSD)

Drag the structure with the mouse to rotate

References

  1. Paoletti F, de Chiara C, Kelly G, Covaceuszach S, Malerba F, Yan R, Lamba D, Cattaneo A, Pastore A. Conformational Rigidity within Plasticity Promotes Differential Target Recognition of Nerve Growth Factor. Front Mol Biosci. 2016 Dec 26;3:83. doi: 10.3389/fmolb.2016.00083. eCollection, 2016. PMID:28083536 doi:http://dx.doi.org/10.3389/fmolb.2016.00083
  2. Paoletti F, de Chiara C, Kelly G, Covaceuszach S, Malerba F, Yan R, Lamba D, Cattaneo A, Pastore A. Conformational Rigidity within Plasticity Promotes Differential Target Recognition of Nerve Growth Factor. Front Mol Biosci. 2016 Dec 26;3:83. doi: 10.3389/fmolb.2016.00083. eCollection, 2016. PMID:28083536 doi:http://dx.doi.org/10.3389/fmolb.2016.00083
  3. Tiveron C, Fasulo L, Capsoni S, Malerba F, Marinelli S, Paoletti F, Piccinin S, Scardigli R, Amato G, Brandi R, Capelli P, D'Aguanno S, Florenzano F, La Regina F, Lecci A, Manca A, Meli G, Pistillo L, Berretta N, Nistico R, Pavone F, Cattaneo A. ProNGF\NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice. Cell Death Differ. 2013 Aug;20(8):1017-30. doi: 10.1038/cdd.2013.22. Epub 2013, Mar 29. PMID:23538417 doi:http://dx.doi.org/10.1038/cdd.2013.22
  4. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014 Apr;74(6):619-26. doi: 10.1007/s40265-014-0208-6. PMID:24691709 doi:http://dx.doi.org/10.1007/s40265-014-0208-6
  5. Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014 Apr;74(6):619-26. doi: 10.1007/s40265-014-0208-6. PMID:24691709 doi:http://dx.doi.org/10.1007/s40265-014-0208-6
Personal tools